Slingshot members are tracking this event:

Gilead (GILD) Initiates Dosing in Phase 2b/3 SELECTION Trial Evaluating Filgotinib in Moderately to Severely Active Ulcerative Colitis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 12, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Dosing Initiation, Phase 2b/3, Selection, Filgotinib, Ulcerative Colitis